Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).

Marcus Lind; Irl B Hirsch; Jaakko Tuomilehto; Sofia Dahlqvist; Ole Torffvit; Nils-Gunnar Pehrsson

doi:10.1016/j.pcd.2014.07.010

Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).

Marcus Lind, Irl B Hirsch, Jaakko Tuomilehto, Sofia Dahlqvist, Ole Torffvit, Nils-Gunnar Pehrsson

Nephrology

Research output: Contribution to journal › Article › peer-review

Abstract

Patients with type 2 diabetes are generally treated in primary care setting and as a final treatment step to obtain good glycaemic control, multiple daily insulin injections (MDI) are generally used. The aim of this study is to evaluate the effect of GLP-1 analogue liraglutide on glycaemic control in patients with type 2 diabetes treated with MDI with inadequate glycaemic control.

Original language	English
Pages (from-to)	15-22
Journal	Primary Care Diabetes
Volume	9
Issue number	1
DOIs	https://doi.org/10.1016/j.pcd.2014.07.010
Publication status	Published - 2015

Subject classification (UKÄ)

Clinical Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.pcd.2014.07.010

http://www.ncbi.nlm.nih.gov/pubmed/25175385?dopt=Abstract

Fingerprint

Dive into the research topics of 'Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).'. Together they form a unique fingerprint.

Cite this

Lind, M., Hirsch, I. B., Tuomilehto, J., Dahlqvist, S., Torffvit, O., & Pehrsson, N.-G. (2015). Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial). Primary Care Diabetes, 9(1), 15-22. https://doi.org/10.1016/j.pcd.2014.07.010

@article{56f58f5bf09d4e8ea6d8288a4c63a4d7,

title = "Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).",

abstract = "Patients with type 2 diabetes are generally treated in primary care setting and as a final treatment step to obtain good glycaemic control, multiple daily insulin injections (MDI) are generally used. The aim of this study is to evaluate the effect of GLP-1 analogue liraglutide on glycaemic control in patients with type 2 diabetes treated with MDI with inadequate glycaemic control.",

author = "Marcus Lind and Hirsch, \{Irl B\} and Jaakko Tuomilehto and Sofia Dahlqvist and Ole Torffvit and Nils-Gunnar Pehrsson",

year = "2015",

doi = "10.1016/j.pcd.2014.07.010",

language = "English",

volume = "9",

pages = "15--22",

journal = "Primary Care Diabetes",

issn = "1878-0210",

publisher = "Elsevier",

number = "1",

}

Lind, M, Hirsch, IB, Tuomilehto, J, Dahlqvist, S, Torffvit, O & Pehrsson, N-G 2015, 'Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).', Primary Care Diabetes, vol. 9, no. 1, pp. 15-22. https://doi.org/10.1016/j.pcd.2014.07.010

Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial). / Lind, Marcus; Hirsch, Irl B; Tuomilehto, Jaakko et al.
In: Primary Care Diabetes, Vol. 9, No. 1, 2015, p. 15-22.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).

AU - Lind, Marcus

AU - Hirsch, Irl B

AU - Tuomilehto, Jaakko

AU - Dahlqvist, Sofia

AU - Torffvit, Ole

AU - Pehrsson, Nils-Gunnar

PY - 2015

Y1 - 2015

N2 - Patients with type 2 diabetes are generally treated in primary care setting and as a final treatment step to obtain good glycaemic control, multiple daily insulin injections (MDI) are generally used. The aim of this study is to evaluate the effect of GLP-1 analogue liraglutide on glycaemic control in patients with type 2 diabetes treated with MDI with inadequate glycaemic control.

AB - Patients with type 2 diabetes are generally treated in primary care setting and as a final treatment step to obtain good glycaemic control, multiple daily insulin injections (MDI) are generally used. The aim of this study is to evaluate the effect of GLP-1 analogue liraglutide on glycaemic control in patients with type 2 diabetes treated with MDI with inadequate glycaemic control.

UR - https://www.scopus.com/pages/publications/84920614644

U2 - 10.1016/j.pcd.2014.07.010

DO - 10.1016/j.pcd.2014.07.010

M3 - Article

C2 - 25175385

SN - 1878-0210

VL - 9

SP - 15

EP - 22

JO - Primary Care Diabetes

JF - Primary Care Diabetes

IS - 1

ER -

Lind M, Hirsch IB, Tuomilehto J, Dahlqvist S, Torffvit O, Pehrsson NG. Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial). Primary Care Diabetes. 2015;9(1):15-22. doi: 10.1016/j.pcd.2014.07.010

Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this